Regenerative biologics supplier for Indianapolis orthopedic practices

How orthopedic practices qualify a biologics vendor

Orthopedic groups and ambulatory surgery centers generally run a new biologics supplier through the same qualification steps they use for any tissue or implant vendor: confirming the entity is a licensed distributor, requesting the HCT/P registration and donor eligibility paperwork for the specific lot or product line under consideration, and routing the regulatory review through the practice's compliance officer or medical director before a purchasing decision is made.

Because Wharton's jelly allografts and exosome products sit under different parts of the federal regulatory framework, practices usually ask a distributor to separate the two product families in any proposal rather than treating them as interchangeable line items.

• Request current lot documentation before the first order
• Route regulatory review through the practice's compliance officer or medical director
• Keep Wharton's jelly and exosome product lines in separate evaluation tracks

NPI-verified accounts and ordering

Precision Biologics opens accounts only for licensed professionals, and account setup requires a valid NPI number tied to the ordering provider or practice. For an Indianapolis-based orthopedic practice, that means the physician or the practice's designated purchasing contact supplies NPI information during onboarding, and the account is matched against that record before pricing or ordering access is released.

Pricing is not published and is available only to verified accounts, which keeps procurement conversations specific to the practice's own documentation requests rather than a generic price list.

Receiving cold-chain shipments in the Midwest

Cryopreserved Wharton's jelly products ship overnight on dry ice in validated containers and are held at -80 degrees Celsius prior to shipment; lyophilized formats are shelf-stable and do not require cryogenic storage. Practices in the Indianapolis-Carmel metro area, like practices anywhere else Precision Biologics ships, are expected to have a receiving process that logs the shipment on arrival and confirms the cold-chain indicator before the product is placed into storage.

Each tissue lot carries a unique lot identifier, and clinics are expected to track use of the product by lot at the patient record level for traceability.

Verifying credentials and setting up an account

Precision Biologics does not advise on clinical use, dosing, or procedures, and recommends that an Indianapolis practice confirm its own standing with the Indiana medical board and consult its own counsel before adding any biologic product line, regardless of supplier. Precision Biologics supports account setup by making registration and licensure documentation, lot-specific certificates of analysis, and donor eligibility summaries available on request, and by offering physician-level calls focused on product documentation rather than clinical guidance.

These products are not FDA approved or licensed for any disease or condition. Information here is for licensed healthcare professionals and is not medical or legal advice.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.